Aldeyra Therapeutics, Inc.
Veridion Score
Composite trend over time
Why is ALDX moving today?
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ALDX.
ALDX insider activity
Aldeyra Therapeutics, Inc.
No multi-insider buying cluster in the last 90 days
Net buying: $423K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | 2026-06-03 | Brady Todd C | Insider | buy | $1.67 | 250,000 | 1,721,298 | $418K | SEC Form 4 |
| 2026-03-20 | 2026-03-19 | DOUGLAS RICHARD | Insider | buy | $1.40 | 70,000 | 195,000 | $98K | SEC Form 4 |
| 2026-03-19 | 2026-03-18 | Alfieri Michael | Insider | buy | $1.42 | 5,000 | 7,500 | $7K | SEC Form 4 |
| 2025-08-15 | 2025-08-13 | Alfieri Michael | Insider | buy | $5.30 | 2,500 | 2,500 | $13K | SEC Form 4 |
| 2025-08-13 | 2025-08-11 | Machatha Stephen | Insider | sell | $5.15 | 22,073 | 221,799 | $114K | SEC Form 4 |
ALDX contract awards, year to date.
Public federal awards linked to this ticker.
ALDX lobbying filings, year to date.
Registered lobbying filings matched to Aldeyra Therapeutics, Inc..